Asia-Pacific Dry Eye Syndrome Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Asia-Pacific Dry Eye Syndrome Market Segmentation, By Type (Evaporative Dry Eye Syndrome and Aqueous Deficient Dry Eye Syndrome), By Product (Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogues, and Others), By Dosage (Liquid Drops, Gel, Ointment, Emulsion, and Others), By Formulation Type (Preservative Based, Non-Preservative Based), By Container Type (Single Dose, Multi-Dose), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By End User (Hospitals, Homecare, Specialty Clinics, and Others)-Industry Trends and Forecast to 2032

Dry Eye Syndrome Market Size

• The Asia-Pacific Dry Eye Syndrome market size was valued at USD 1.63 billion in 2024 and is expected to reach USD 2.73 billion by 2032, at a CAGR of 7.1% during the forecast period
• This growth is driven by rising prevalence of dry eye disease due to digital screen exposure, growing geriatric population, and increased awareness about ocular surface disorders among consumers.

Dry Eye Syndrome Market Analysis

• Dry Eye Syndrome (DES) is a multifactorial ocular surface disease characterized by loss of tear film homeostasis. Common symptoms include irritation, blurred vision, and discomfort. The Asia-Pacific region has experienced a surge in DES cases due to rising screen time, urban pollution, and hormonal changes.
• Non-invasive diagnostic technologies, increasing patient education campaigns, and widespread OTC availability of lubricating drops are enhancing early diagnosis and treatment rates. Major advances in lipid-based formulations and inflammation-targeted drugs are expected to reshape the treatment landscape.
• India and China are projected to lead market share owing to large population base, increasing healthcare expenditure, and robust local manufacturing of generics and ophthalmic solutions.  
• Japan and South Korea are experiencing a rise in DES prevalence among aging and tech-savvy demographic
• In 2025, the Artificial Tears segment is expected to hold the largest share of 49.8%, due to their ease of availability, affordability, and established use in first-line therapy.

 Report Scope and Dry Eye Syndrome Market Segmentation 

Dry Eye Syndrome Market Trends

"Shift Toward Personalized Ocular Therapies"

• The Asia-Pacific market is increasingly focused on personalized care strategies in DES management. Innovations in drug-delivery such as nanodrops, biodegradable punctal plugs, and gene-targeted anti-inflammatory therapies are advancing treatment precision.
•  Moreover, companies are developing AI-driven diagnostic platforms and digital apps for real-time symptom tracking. Wearable blink sensors and environmental exposure monitors are also entering the market to offer holistic treatment insights. • This trend is especially prominent in urban markets of South Korea, Japan, and Singapore, where demand for premium and tech-integrated dry eye solutions is rising.

Dry Eye Syndrome Market Dynamics

Driver

"High Screen Time and Environmental Risk Factors"

• DES incidence is strongly correlated with lifestyle risk factors such as prolonged exposure

to digital devices, low blink rates, use of contact lenses, and exposure to urban pollutants

• Government initiatives, employer wellness programs, and ophthalmic associations are increasingly focusing on early intervention and public education, boosting diagnosis and treatment rates.

Opportunity

"Emergence of Advanced, Long-Lasting Eye Drop Formulations"

• Ongoing R&D in mucin-mimetic, lipid-layer stabilizing, and anti-inflammatory drug segments is opening new treatment pathways.

• Emerging countries in Southeast Asia are being targeted for clinical trials and low-cost access models by multinational ophthalmic companies.

Restraint/Challenge

 "Affordability and Awareness Gaps in Tier-2 and Rural Areas"

•  Despite the increase in product availability, high out-of-pocket expenses and poor awareness levels in semi-urban and rural Asia-Pacific remain barriers to market penetration.
•  For example, a 2023 study by the Asia-Pacific Ocular Health Society found that 48% of rural DES patients in Indonesia delayed treatment due to cost and lack of diagnosis.

Dry Eye Syndrome Market Scope

The market is segmented on the basis of product type, formulation, distribution channel, indication, and end user.

In 2025, the Artificial Tears segment is projected to dominate the market with the largest share in product segment

 In 2025, the Artificial Tears segment is expected to hold the largest share of 49.8%, due to their ease of availability, affordability, and established use in first-line therapy.

The Evaporative Dry Eye Syndrome segment is expected to account for the largest share during the forecast period in type segment

 In 2025, the Evaporative Dry Eye Syndrome segment is anticipated to capture a 58.6% share, driven by high prevalence due to screen-related eye fatigue and meibomian gland dysfunction.

Dry Eye Syndrome Market Regional Analysis

“India Holds the Largest Share in the Dry Eye Syndrome Market”

India dominates due to large unmet patient need, increased ophthalmologist availability, and rapid growth of digital device usage.

Dry Eye Syndrome Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focU.S. related to market.

The Major Market Leaders Operating in the Market Are:

• Santen Pharmaceutical Co., Ltd. (Japan)
• Sun Pharmaceutical Industries Ltd. (India)
• Allergan (U.S.)
• Otsuka Holdings Co., Ltd. (Japan)
• Novartis AG (Switzerland)
• Bausch Health Companies Inc. (Canada)
• Johnson & Johnson Vision (U.S.)
• Rohto Pharmaceutical Co., Ltd. (Japan)
• Sentiss Pharma Pvt. Ltd. (India)
• Alcon Inc. (Switzerland)

Latest Developments in Asia-Pacific Dry Eye Syndrome Market

• In February 2025, Rohto launched preservative-free dry eye drops in Thailand.
• In March 2025, Sentiss announced expansion of its dry eye product line in India.
• In January 2025, Santen received Japanese approval for its new lipid-layer targeting therapy.
• In April 2025, Alcon partnered with a Chinese health-tech firm to launch AI-based dry eye diagnostic solutions.

SKU-44906